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OBJECTIVES The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above
clopidogrel in non–ST-elevation myocardial infarction (NSTEMI) patients before an
expeditive coronary intervention.
BACKGROUND Although thienopyridines and glycoprotein (GP) IIb/IIIa antagonists are often co-prescribed
in the context of NSTEMI, the antiplatelet interaction of these agents is poorly described and
the superiority of GP IIb/IIIa antagonists above thienopyridine treatment alone is not clear.
METHODS Thirty-two NSTEMI patients treated with aspirin and enoxaparin were studied using flow
cytometry to define parameters of platelet activation with a panel of agonists before
clopidogrel, after clopidogrel, and during an eptifibatide infusion following the clopidogrel
load.
RESULTS After platelet activation with adenosine diphosphate, thrombin receptor-activating peptide,
or U46-619, relative reductions in conformationally activated GP IIb/IIIa receptor expression
(evaluated with PAC-1) of 48%, 43%, and 33%, respectively (all p  0.0001), were seen with
clopidogrel, but further 80%, 78%, and 72% (all p  0.0001) reductions were seen with
eptifibatide. With the same agonists, fibrinogen binding was significantly reduced after
clopidogrel by 70%, 64%, and 81% (all p  0.0001) and again further reduced with
eptifibatide by 90%, 95%, and 69% (all p  0.0001). The total number of GP IIb/IIIa
receptors (measured as P2 expression) and P-selectin expression fell after clopidogrel, after ex
vivo stimulation with the same agonists; however, both parameters increased slightly during
the eptifibatide infusion.
CONCLUSIONS The activated GP IIb/IIIa expression and fibrinogen binding findings indicate that eptifi-
batide provides significant potent antiplatelet activity above aspirin and clopidogrel, suggest-
ing additive immediate protection in the treatment of NSTEMI. The P2 and P-selectin
findings suggest the possibility of a partial agonist and/or pro-inflammatory effect. (J Am
Coll Cardiol 2004;43:162–8) © 2004 by the American College of Cardiology Foundation
The traditional antithrombotic management of unstable
angina and non–ST-elevation myocardial infarction
(NSTEMI) is based on aspirin and heparin. A number of
newer, more potent antiplatelet agents have been developed
separately and incorporated into clinical practice. In addi-
tion to aspirin, the adenosine diphosphate (ADP) receptor
antagonist clopidogrel has been shown to be of clinical
benefit in the treatment of acute coronary syndrome patients
(1). Similar positive results have been found with small-
molecule glycoprotein (GP) IIb/IIIa antagonists in the
medical stabilization of unstable angina/NSTEMI patients,
especially in diabetic and troponin-positive patients (2,3).
Because they have been developed and trialed indepen-
dently, however, data on the antiplatelet interaction of these
drugs are very limited, and it is not known whether additive
effects can be expected, as no study has ever compared a
double antiplatelet regimen of aspirin and clopidogrel with
a triple regimen of aspirin, clopidogrel, and GP IIb/IIIa
antagonist in this situation. Glycoprotein IIb/IIIa antago-
nists remain expensive drugs requiring IV bolus plus infu-
sion delivery, and it is therefore important to know whether
they provide a significant benefit above that of clopidogrel
during the period of medical stabilization preceding cathe-
terization. We investigated the effects of clopidogrel and
eptifibatide prescribed successively in addition to aspirin and
enoxaparin in a cohort of NSTEMI patients before early
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angiography. The primary objective was to establish
whether better control of GP IIb/IIIa receptor expression
and fibrinogen (Fg) binding could be achieved with both
agents than with clopidogrel alone in the context of the
expeditive care of NSTEMI patients. The secondary objec-
tive was to evaluate the early effect of a loading dose of
clopidogrel on top of aspirin on the same parameters.
METHODS
Enrollment criteria. Study inclusion criteria included men
or non-pregnant women 18 years hospitalized with
NSTEMI, defined as angina at rest or crescendo angina,
and electrocardiographic (ECG) ST-T-segment changes
(ST-segment depression or transient elevation of at least 0.1
mV or T-wave changes in at least 2 ECG leads). A positive
troponin I test was a requirement (0.1 g/ml), and
coronary angiography had to be indicated. Exclusion criteria
were contraindications to aspirin, clopidogrel, or eptifi-
batide; severe renal insufficiency (creatinine clearance 30
ml/min); vitamin K antagonist treatment in the preceding
five days; and treatment with other anticoagulants or
thrombolytics.
Study design and hypothesis. The trial was a single-
center, platelet end-point study in which each patient was
their own control. The NSTEMI patients treated on
admission with aspirin, 500 mg IV (followed by 75 mg/day
orally), and enoxaparin, 1 mg/kg twice a day subcutane-
ously, were considered for enrollment in the Platelet
activity Extinction in non–Q-wave myocardial infarction
with Aspirin, Clopidogrel and Eptifibatide (PEACE)
study. Appropriate anti-anginal treatment (beta-blocker,
nitrate, calcium antagonist) was used at the discretion of
the clinician. When patients were eligible for enrollment,
and after giving informed, written consent, the first blood
sample (baseline, or T1) was taken on aspirin and enoxapa-
rin treatment. Immediately after this, an oral loading dose
(300 mg) of clopidogrel was given. The second sample (clopi-
dogrel effect, or T2) was taken at least 3 h after clopidogrel
administration. Immediately after T2, an IV bolus of eptifi-
batide, 180 g/kg IV, followed by an infusion of 2 g/kg per
minute, was administered. A third sample was taken 12 h
after the start of the eptifibatide infusion (eptifibatide effect, or
T3), just before cardiac catheterization.
The primary purpose of the study was to evaluate whether
eptifibatide had an additive effect to that of clopidogrel. The
secondary objective was to evaluate the effect of clopidogrel.
The null hypothesis was that eptifibatide offered no signif-
icant antiplatelet effect beyond that of clopidogrel.
Biologic measurements at T1, T2, and T3. Samples of
venous blood were collected both on EDTA for platelet
count and on PPACK to avoid calcium chelation (75
mol/l, Haematologic Technologic Inc., Essex Junction,
Vermont) for flow cytometry and transferred immediately to
the laboratory for analysis. PPACK was chosen as an
anticoagulant rather than trisodium citrate because of pre-
vious observations that Ca2 chelation afforded by citrate
may alter the interaction between GP IIb/IIIa antagonists
and platelet receptor by a number of possible mechanisms
(4–6). The platelet count and volume were determined
using the STKS automatic blood cell counter (Coultronics
France SA, Margency, France). Platelet parameters were
immediately measured on whole blood (diluted 1/4 with
saline for GPs, non-diluted for microparticles). Fluorescein
isothiocyanate (FITC) or phycoerythrin (PE)-conjugated
monoclonal antibodies (MAb) were from Beckman Coulter
(Roissy, France) and Becton Dickinson (Le Pont de Claix,
France). Preliminary studies have defined the optimal
amount of each antibody that would provide maximum
antigen labeling and minimum unspecific binding. The flow
cytometer was a Calibur fluorescence-activated cell sorter
from Becton Dickinson. Flow cytometry was used to mea-
sure the degree of activation of circulating platelets in the
resting state and after ex vivo stimulation by 0.6 mmol/l
arachidonic acid (Biodata Corp., Horsham, Pennsylvania),
5 mol/l ADP (Coulter, Margency, France), 25 mol/l
thrombin receptor-activating peptide (TRAP) (Neosystems,
Strasbourg, France), and 1 mol/l U46-619, a representa-
tive agonist for the thromboxane A2 receptor (Calbiochem,
Merck, Darmstadt, Germany). Regarding the doses, a
relatively low dose of ADP was chosen because of the high
sensitivity of the P2Y12 (thienopyridine-sensitive) ADP
receptor subtype (7). Although TRAP is a thrombin ago-
nist, it is very much less potent than thrombin (8), and this
dose induced optimal subtotal stimulation. Epinephrine was
not used because of the marked heterogeneity of interindi-
vidual response (9). Platelet parameters were quantified as
follows: total GP IIb/IIIa complexes using P2 (anti-CD41)
MAb, activated GP IIb/IIIa complexes using PAC-1 MAb;
platelet Fg binding using anti-human Fg chicken MAb
(Biopool International, Ventura, California); and P-selectin
expression using anti-CD62P MAb. The fluorescence in-
tensity was determined using a flow cytometer (FACScali-
bur, 3 colors with loader, Becton Dickinson) and Cell Quest
software. For quantification, calibration beads in latex were
used coated with mouse immunoglobulins (3 m diameter;
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350, 7800, 22,000, and 53,000 immunoglobulins/bead).
Flow cytometry defined four peaks of fluorescence intensity,
corresponding to the four immunoglobulin densities, and
allowed a calibration curve to be drawn (fluorescence inten-
sity as a function of the number of epitopes for the
antibody). For platelet analyses, all fluorescence intensities
were translated into a number of epitopes per platelet.
Platelet-derived microparticles were assayed using a PE-
labeled anti-GP IIb/IIIa MAb (clone P2, anti-CD41)
associated with FITC-labeled annexin-V, which binds to
activated cellular membrane phospholipids and is not inhib-
ited by the presence of eptifibatide. Additionally, micropar-
ticles were discriminated by size using a specific gate defined
with 0.8-m diameter latex beads (Sigma, Lyon, France).
The number of microparticles is expressed as a function of
the total whole blood volume and as a function of the
platelet count.
Statistical analysis. The main comparison considered in
the present study was defined, a priori, as the comparison
between T3 and T2, thus exploring the additive effect of
eptifibatide after clopidogrel administration. A comparison
between T2 and T1 (i.e., effect of clopidogrel) was consid-
ered, a priori, as secondary. In order to limit the inflation of
the alpha risk, a conservative approach was used. First, any
possible difference between the three treatments (i.e., cor-
responding to 3 different times within the same patient) was
tested by analysis of variance (ANOVA). The conservative
Huyn-Feldt criteria (10) were used, rather than the classic F
test, to estimate the significance level. Only if ANOVA
allowed rejection of the null hypothesis of an absence of a
difference between the three treatments, were 2  2
comparisons made using appropriate contrasts. Because a
hierarchy of comparisons was made, a priori, defining a
single main comparison, no adjustment of the alpha risk was
required at this level. Version 8.1 of SAS (from the SAS
Institute) was used in the present study. Results are ex-
pressed as the mean value  SEM. For differences between
time points T1-T2 and T2-T3, the mean values of the
differences for individual patients are used in the analysis
(), and the significance value is calculated for . The
relative reduction (RR) or relative increase (RI), calculated
as the mean reduction/increase in , is also given. Graph-
ically, the mean values of all patient data at T1, T2, and T3
are presented with corresponding SEMs. A significance
level of 0.05 was considered significant for individual
comparisons, as is conventionally the case in studies of this
kind. However, when correcting for multiple comparisons
to increase the robustness of the conclusions, the signifi-
cance value is p  0.0036. When the Bonferonni correction
results in a significant difference (p  0.05) becoming
non-significant, “corrected NS” is indicated in parenthesis
and subsequently discussed.
Ethical approval. The protocol was approved by the Pitie´-
Salpe´trie`re Ethics Committee, and written, informed con-
sent was obtained from all patients.
RESULTS
Study population. Thirty-two NSTEMI patients were
recruited to the study. Patient characteristics were (mean 
SEM or number [%] of patients): age 64.3 2.8 years, body
mass index 26.0  0.82 kg/m2, creatinine clearance 77.3 
5.7 ml/min, smoker (n  15 [47%]), hyperlipidemia (n  9
[28%]), hypertension (n  15 [47%]), diabetes (n  12
[38%]), previous myocardial infarction (n  8 [25%]),
previous coronary artery bypass graft surgery (n  1 [3%]),
previous percutaneous coronary intervention (PCI; n  5
[16%]), and Killip class I (n  25 [78%]), class II (n  1
[3%]), and class III (n  6 [19%]). The mean troponin I
level at presentation was 6.9  2.2 g/ml.
Seventeen patients underwent PCI (53%), and all PCI
procedures involved the deployment of at least one stent.
Four patients underwent bypass surgery (13%). Of the
remaining 11 patients, one died before angiography, one
died before planned bypass surgery, and the remainder had
anatomy deemed either not severe enough or not suitable
for revascularization. By 30 days, two patients had died (6%)
and three others had a myocardial infarction (9%).
Flow cytometry. BASAL STATE. In the basal state, reflecting
the activation status of circulating platelets, PAC-1
(1,500) and anti-Fg binding (200) remained low at all
time points (MAb binding expressed as the mean number of
binding sites per platelets throughout). Despite these low
levels of expression, both parameters were further reduced
with clopidogrel and again with eptifibatide. Binding of
PAC-1 fell significantly after clopidogrel (  130, p 
0.0001; RR 37%,) and further with eptifibatide (  29,
p  0.0001; RR 22%). Anti-Fg binding decreased signifi-
cantly after clopidogrel (  22, p  0.0006; RR 21%)
but increased with eptifibatide (  9, p  NS; RI 37%).
Expression of P2 in the basal state did not change signifi-
cantly with either clopidogrel (818, pNS; RR 3%,)
or eptifibatide (  3071, p  NS; RI 9%). P-selectin
expression in the basal state was also low (all values1,000)
at all time points, with no significant differences after
clopidogrel (  22, p  NS; RR 6%) or eptifibatide
(  26, p  NS; RI 18%). Because baseline expression
of PAC-1, Fg binding, and P-selectin expression were low
in this population (as they were with the relatively weak
agonist, arachidonic acid), the results were also expressed as
percentage of platelets fixing the relevant antibody. The
same comparisons were made, and the exact same results
were found (data not shown).
ARACHIDONIC ACID. Ex vivo arachidonic acid–induced
expression of activation epitopes reflects the degree of
aspirin blockade and low levels of both PAC-1 (92  9)
and anti-Fg (122  49) seen. Although only 11 of the
patients were receiving long-term aspirin therapy, all re-
ceived 500 mg IV on admission, and the arachidonic acid
data indicated a marked aspirin response and no evidence of
aspirin resistance in the patients studied. However, further
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platelet inhibition was measured with a significant decrease
in PAC-1 after clopidogrel (  11, p  0.0001; RR
13%) and a further significant fall with eptifibatide ( 
45, p  0.0001; RR 46%). Anti-Fg was unchanged after
clopidogrel (  50 p  NS; RR 7%). There was no
further change with eptifibatide (  5 p  NS; RI 9%).
P2 expression remained unchanged from baseline ( 
26, p NS; RR 1%) and with eptifibatide (  84 p
NS; RI 0%). P-selectin tended to decrease after clopidogrel
(  21, p  NS; RR 9%) and tended to increase with
eptifibatide (  25, p  NS; RI 21%).
ADENOSINE DIPHOSPHATE. With ADP ex vivo platelet
activation, the ADP responsiveness pathway is specifically
tested, and there were significant reductions in PAC-1
expression (  9,128, p 0.0001; RR 48%), Fg binding
(  54,777, p  0.0001; RR 71%) (Fig. 1), P2
expression (  5,717, p  0.017 [corrected NS];
RR 9%), and P-selectin expression (  874, p  0.001;
RR 38%) (Fig. 2) after clopidogrel. With eptifibatide,
marked further significant reductions were seen with
both PAC-1 expression (  7,485, p  0.0001; RR
80%) and Fg binding (  10,896, p  0.0001; RR 90%)
(Fig. 1). Both P2 ( 14,321, p 0.018 [corrected NS];
RI 34%) and P-selectin (  273, p  0.012 [corrected
NS]; RI 47%) expression increased significantly, however
(Fig. 2).
TRAP. With TRAP as the agonist, when testing the throm-
bin responsiveness pathway, there were significant reduc-
tions in PAC-1 expression (  8,677, p  0.0001; RR
43%), Fg binding (  46,682, p  0.0001; RR 64%)
(Fig. 1), and P-selectin expression (  1,574, p 
0.0023; RR 15%) (Fig. 2) after clopidogrel, whereas there
was a non-significant trend toward a fall in P2 ( 
4,137, p  NS; RR 5%). With eptifibatide, there was a
further significant reduction in PAC-1 expression ( 
8,421, p  0.0001; RR 78%) and Fg binding ( 
22,093, p  0.0001; RR 95%), whereas there was a trend
toward a rise in both P2 (  7,844, p  NS; RI 15%)
and P-selectin (  1,114, p  NS; RI 29%), although
neither reached significance (Fig. 2).
U46-619. With U46-619 as the agonist, when testing the
thromboxane A2 responsiveness pathway, there were signif-
icant reductions in PAC-1 expression (  9,820, p 
Figure 1. Charts of conformationally active glycoprotein IIb/IIIa receptor expression (PAC-1) and anti-fibrinogen (Fg) before clopidogrel administration
(T1),2 h after clopidogrel (T2), and during eptifibatide infusion (T3). Receptor expression and Fg binding are expressed on the y axis as the mean number
of sites expressed per platelet. ADP  adenosine diphosphate.
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0.0001; RR 33%), Fg binding (  97,252, p  0.0001;
RR 81%) (Fig. 1), P2 expression (  8,997, p  0.026
[corrected NS]; RR 11%), and P-selectin expression ( 
4,071, p  0.0001; RR 48%) (Fig. 2) after clopidogrel.
With eptifibatide, there was a further significant reduction
in PAC-1 expression (  11,116, p  0.0001; RR 72%)
and Fg binding (  33,821, p  0.0001; RR 69%) (Fig.
1). However, P2 expression rose significantly with eptifi-
batide (  23,915, p  0.0022; RI 53%), and P-selectin
expression showed a marked trend toward increasing ( 
4,059, p  NS; RI 199%).
Platelet microparticles. There was a non-significant fall in
the platelet microparticles as a function of blood volume (
 17,635, p  NS; RR 8.%) after clopidogrel, but a
significant further fall with eptifibatide (  31,991, p 
0.001; RR 32%). The platelet microparticles as a function of
platelet count did not change with clopidogrel (  109,
pNS; RR 8%), but it fell significantly with eptifibatide (
 165, p  0.0005; RR 32%) (Fig. 3).
Platelet count/volume. There was no significant change in
the baseline (pre-clopidogrel) platelet count or volume after
clopidogrel or eptifibatide treatment (data not shown).
Figure 2. Charts of total glycoprotein IIb/IIIa receptor expression (P2) and P-selectin expression before clopidogrel administration (T1), 2 h after
clopidogrel (T2), and during eptifibatide infusion (T3). Receptor expression and fibrinogen binding are expressed on the y axis as the mean number of sites
expressed per platelet. “ns” is indicated in parenthesis for p values0.05 but0.0036 and therefore are not significant after Bonferonni correction. ADP
adenosine diphosphate.
Figure 3. Charts of platelet microparticle count as a function of blood
volume (MPV) (top panel) and platelet count (MPP) (bottom panel) on
the y axis before clopidogrel administration (T1), 2 h after clopidogrel
(T2), and during eptifibatide infusion (T3).
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DISCUSSION
Low levels of conformationally active GP IIb/IIIa expres-
sion, as revealed by PAC-1 binding and Fg binding, were
measured in the baseline state (in patients treated with
aspirin and enoxaparin), indicating low but measurable
activation levels of circulating platelets in the study patients
with NSTEMI. These levels are similar to those seen in our
previous study using similar methods, demonstrating low
levels of peripheral blood platelet activation in such patients
treated with aspirin and enoxaparin, indicating a consistency
of technique (8). Other investigators have observed similar
levels (11). The apparent discrepancy between the PAC-1
and Fg binding levels may be due to the fact that Fg can
polymerize; thus, the anti-Fg MAb may bind several Fg
ligands associated with a single GP IIb/IIIa receptor.
Although the biologic relevance of such low levels of
epitopes could be questioned, both activated GP IIb/IIIa
expression and Fg binding fell significantly after clopidogrel
and fell further with eptifibatide, although this was only
significant for PAC-1. The ex vivo arachidonic acid stim-
ulation indicated a significant aspirin effect in all patients
with profound inhibition of the arachidonic acid pathway
and low levels of IIb/IIIa activation, Fg binding, and
P-selectin activation. Interestingly, there was further sup-
pression of IIb/IIIa expression and a trend toward reduced
Fg binding with clopidogrel, suggesting further inhibition
of the arachidonic acid pathway beyond the aspirin effect.
With ADP, TRAP, and U46-619 as the ex vivo agonists
of platelet stimulation, clopidogrel reduced the induction of
PAC-1 binding site expression and Fg binding. With
eptifibatide, however, both parameters were markedly and
significantly further reduced consistently with all three
agonists. This major finding of the study indicates that GP
IIb/IIIa activation induced by these potent agonists is only
partially suppressed by clopidogrel alone and is far better
controlled by the addition of eptifibatide therapy (Fig. 1).
The similar pattern observed with platelet microparticles
further confirms the profound added platelet inhibitory
effect with eptifibatide when given in addition to aspirin and
clopidogrel, and importantly, as it reflects in vivo change, it
further supports the validity of the ex vivo stimulation
findings. This additive antiplatelet effect may be particularly
important in high-risk patients such as the study NSTEMI
patients heading to the catheterization laboratory for an-
giography and often PCI, triggering further platelet activa-
tion. There was no temporal control in this study, because
the patients were managed according to current clinical
guidelines (12); however, we have shown that in acute
coronary syndrome patients, there is no appreciable tempo-
ral change over 48 h when antiplatelet therapy is not
modified (8). There was no group without eptifibatide
because, as discussed, patients were managed according to
current guidelines and standard local practice at our insti-
tution, allowing ethical approval by our Institutional Review
Board. Equally, there was no group with eptifibatide and no
clopidogrel, for the same reasons. Regarding the use of the
ANOVA test before further analysis, this allows more
robust conclusions and reinforces the conclusions of the
present study. The secondary findings with P2 and
P-selectin expression were unexpected. Although ex vivo–
stimulated expression of both parameters with ADP,
TRAP, and U46-619 decreased after clopidogrel, they both
increased slightly during eptifibatide infusion. This reached
statistical significance with ADP for both parameters and
with U46-619 for P2, while the same trend was seen with
TRAP. Analysis of the individual data points indicated that
this was a group effect and not due to a few outliers. The
statistical power was limited by the sample size, and we
cannot exclude the possibility of chance findings. Further-
more, when applying Bonferonni correction, although there
was a fall in P-selectin with all three agonists, the only
significant rise was in P2 with U46; however, the same
pattern was consistently seen with three separate agonists.
Platelet degranulation could account for both P-selectin
expression and increased P2 MAb binding due to release of
granular GP IIb/IIIa receptors (not measured while intra-
granular). Alternatively, there could be a direct GP IIb/IIIa
receptor upregulatory effect. The possibility of a partial
agonist effect of GP IIb/IIIa antagonists inducing platelet
activation and Fg binding has been raised in the past
(13–16), although whether biologically important aggrega-
tion is induced in physiologic conditions at therapeutic
doses is debated (17). However, our finding of increased
P-selectin expression is in keeping with that of Cox et al.
(16) in the OPUS-Thrombolysis In Myocardial Infarction
(TIMI)-16 trial and similarly offers a possible mechanism
for the observed detrimental effects of long-term oral GP
IIb/IIIa antagonist therapy (18) and prolonged IV GP
IIb/IIIa antagonist infusions without early PCI (19), the
latter being potentially exaggerated by ongoing shear forces
due to untreated coronary stenoses (20). One could further
hypothesize that prolongation of the eptifibatide infusion in
PEACE may have resulted in still further P-selectin expres-
sion and P2 increase. This raises the question of a possible
pro-thrombotic and/or pro-inflammatory effect through
platelet leukocyte aggregation (20,21), although these sec-
ondary findings regarding P2 and P-selectin must still be
regarded as very preliminary and explorative rather than
demonstrative in view of the small sample size of the study.
In the short term, the potent anti-aggregatory effect of
GP IIb/IIIa receptor blockade is overwhelming and proba-
bly explains the marked efficacy of these agents in PCI
(22–25), including when patients have been pretreated by a
thienopyridine (26–30). Our data also strongly support the
recently published post-hoc analysis of the patients in the
Platelet IIb/IIIa Underpinning the Receptor for Suppres-
sion of Unstable Ischemia Trial (PURSUIT), demonstrat-
ing that the benefit of eptifibatide was confined to patients
having very early intervention (31). It also supports the
concept of a stronger double-bolus regimen and a shorter
infusion of eptifibatide in PCI (26). Together, the results
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from PEACE and the most recent clinical data support the
concept of “expeditive care” of NSTEMI patients with short
infusions of GP IIb/IIIa receptor blockers and early PCI
(22–25) for an extended long-term benefit (32,33).
Conclusions. In high-risk patients, the superior control of
activated platelet GP IIb/IIIa receptor expression and Fg
binding obtained with eptifibatide, in addition to clopi-
dogrel, suggests that clopidogrel alone may not be sufficient
as the “poor man’s IIb/IIIa antagonist.” Our findings suggest
that GP IIb/IIIa blockade may be particularly beneficial in the
short-term treatment of high-risk patients undergoing early
angiography, thus also avoiding the possible downsides of a
prolonged infusion. Eptifibatide remains a potent, rapidly
effective antiplatelet agent, whereas clopidogrel provides an
intermediate, slower antiplatelet effect but also a long-term
secondary prevention after NSTEMI and stenting.
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